Reckitt Benckiser Group Plc

*Prices delayed by at least 15 minutes Get price movement alerts
  • 7,359.50p
  • -46.00p (-0.62%)


Reckitt Benckiser share price: Hargreaves Lansdown weighs in on update

Hargreaves Lansdown weighs in on Reckitt Benckiser after update

Analysts reckon group should be able to recover from ‘self-inflicted’ problems

October 2018


Get Alerts

About Reckitt Benckiser Group Plc

Reckitt Benckiser Group Plc (LON:RB) is producing and marketing household, toiletry, health and personal care products worldwide. Its key brands include Scholl (foot care and comfort footwear products), Veet (hair removal products), Nurofen (a pain-relief medication), Strepsils (a sore throat medication), Durex condoms, Mucinex (a cold/flu medication), Gaviscon, Clearasil (acne treatment products), Finish (automatic dishwashing products), Calgon water softener, Dettol (antiseptic liquids), Wick air freshener and Vanish stain remover, among others.
Reckitt Benckiser brands can be found in nearly 200 countries around the world. The company operates in Europe, North America, Latin America, the Middle East, North Africa, Sub-Saharan Africa, Turkey, Russia and CIS, Australia and New Zealand.
Headquartered in Slough, United Kingdom, the group was established in 1999 through the merger of UK-based Reckitt & Colman plc and Netherlands-based Benckiser NV.
Rakesh Kapoor is Chief Executive Officer.
The group’s latest acquisitions include nutritional supplement and vitamin company Schiff Nutrition in 2012. In 2010, Reckitt Benckiser completed the acquisition of SSL International, adding Durex and Scholl to its powerbrands.
Reckitt Benckiser was fined £10.2 million by the Office of Fair Trading in October 2010 after the company admitted to anti-competitive practices in the supply of its Gaviscon heartburn treatment to the NHS.

Send Feedback. Win £20
0 Brokers added for comparison:
Clear all